Full drug details and pet owner handout can be found at Plumb’s.
Veterinarians managing osteoarthritis in dogs now have a new therapeutic option available. Bedinvetmab (Librela) is FDA-approved to control osteoarthritis pain in dogs.
Pharmacology of Bedinvetmab
Bedinvetmab is a canine IgG monoclonal antibody (mAb) that binds to nerve growth factor (NGF), thus decreasing NGF-mediated processes involved in pain.
Contraindications of Bedinvetmab
Bedinvetmab is contraindicated and should not be used in dogs that are hypersensitive to it, or in dogs that are pregnant, lactating, or intended for breeding. This drug has not been studied in dogs with a history of cruciate ligament rupture in the past 6 months, or in dogs less than 12 months old.
Side Effects of Bedinvetmab
Adverse effects include:
Renal/Urinary: increased BUN, UTI, inappropriate urination
Dermal: bacterial skin infection, dermatitis, dermal mass or cyst, erythema
GI: vomiting, decreased appetite
Musculoskeletal: lameness, rear limb paresis, and individual cases of elbow dysplasia and ulnar cartilage necrosis
A comprehensive look at how to manage osteoarthritis in dogs using bedinvetmab is offered by the experts at Plumb’s — complete drug information and pet owner handout can be found here.